Evidence map›Paper›PMID 31848692›Full record

Observational studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2020

Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study.

Maurizio Battaglia Parodi, Francesco Romano, Alessandro Arrigo, Carlo Di Nunzio, Alessio Buzzotta, Giorgio Alto, Francesco Bandello

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Reply: natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Article
  8. Natural course of the vitelliform stage in best vitelliform macular dystrophy: a five-year follow-up study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Maurizio Battaglia ParodiDepartment of Ophthalmology, Scientific Institute San Raffaele, Vita-Salute University, Milan, Italy.
Francesco RomanoEye Clinic, Department of Biomedical and Clinical Science, Luigi Sacco University Hospital, Milan, Italy.
Alessandro ArrigoDepartment of Ophthalmology, Scientific Institute San Raffaele, Vita-Salute University, Milan, Italy. alessandro.arrigo@hotmail.com.
Carlo Di NunzioDepartment of Ophthalmology, Scientific Institute San Raffaele, Vita-Salute University, Milan, Italy.
Alessio BuzzottaDepartment of Ophthalmology, Scientific Institute San Raffaele, Vita-Salute University, Milan, Italy.
Giorgio AltoDepartment of Ophthalmology, Scientific Institute San Raffaele, Vita-Salute University, Milan, Italy.
Francesco BandelloDepartment of Ophthalmology, Scientific Institute San Raffaele, Vita-Salute University, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe vitelliform stage is the typical phenotypic manifestation of Best vitelliform macular dystrophy (BVMD). As yet, no study has focused specifically on the clinical changes occurring in the vitelliform stage over the follow-up.

methodsThe survey takes the form of a prospective observational study with a 5-year follow-up. Twenty-one eyes of 11 patients in the vitelliform stage were examined annually. The primary outcome was the identification of the changes in the vitelliform lesion over a 5-year follow-up. Secondary outcomes included changes in structural optical coherence tomography (OCT) parameters and the correlation with the BCVA variation over the follow-up.

resultsSpectral domain OCT at baseline showed one subform characterized by solid vitelliform deposition, in 81% of eyes, and another subform characterized by a combination of solid deposition and subretinal fluid, in 19% of eyes. Overall, 62% of eyes showed an increase in the area of vitelliform deposition. Once the maximal area was reached, a progressive flattening of the vitelliform deposition took place, with subsequent flattening of the vitelliform lesion and formation of subretinal fluid. Hyperreflective foci (HF) increased in number as long as the vitelliform area continued to expand, with no variation in HF when the vitelliform lesion flattened or the subretinal fluid formed.

conclusionsThe vitelliform stage reveals more subforms with clinical variations over the follow-up. Our data suggest that the substage before the flattening of the lesion, thus before the so-called subretinal fluid accumulates and when the visual acuity is still high, might offer the best opportunity for an optimal therapeutic approach.

Indexed as

AdolescentAdultChildDisease ProgressionFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansMacula LuteaMaleMiddle AgedProspective StudiesRetinal VesselsTime FactorsTomography, Optical Coherence5-year follow-upBest vitelliform macular dystrophyHyperreflective fociOCTVitelliform stage

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.